Our Focus

We can't eliminate epidemics, but we can minimize their impact.

Political instability, proliferation of global transportation, population expansion, increasing demand for proteins and ecological change are all contributing to increased infectious disease risk. That's why we partner with businesses and governments worldwide to identify and track pathogens from their source, then contextualize the risk based on socioeconomic, political, environmental and other factors.

Play product video
Research
Industry
Government
Our Science

Our analytics enable innovative insurance products.

Years of deep scientific leadership and portfolio-specific asset analysis are our foundation for creating sustainable business tools for a volatile world. By understanding marketplace mechanisms and our partners' needs, we help identify risk transfer and intervention opportunities that would otherwise remain hidden.

Learn more
Lassa Fever Cases 2018 YTD (through 8 April 2018)
Cholera Cases (27 April 2017 - 11 April 2018)
MERS Coronavirus Cases 2018 YTD (thru 9 April 2018)
Influenza A Cases Wave 6 (October 2017 - 7 April 2018)
  • Lassa Fever
  • Cholera
  • MERS Coronavirus
  • Influenza A (H7N9)

Lassa fever is an acute viral haemorrhagic illness of 2-21 days duration that occurs in West Africa. About 80% of people who become infected with Lassa virus have no symptoms. 1 in 5 infections result in severe disease, where the virus affects several organs such as the liver, spleen and kidneys. The overall case-fatality rate is 1%. Observed case-fatality rate among patients hospitalized with severe cases of Lassa fever is 15%.

WHO (2018). Lassa fever fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/fs179/en/ (15 Mar 2018)

Cholera is an acute diarrhoeal disease caused by Vibrio cholerae that can kill within hours if left untreated. Researchers have estimated that each year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide due to cholera. 

 

WHO (2017). Cholera fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/fs107/en/ (27 Nov 2017).

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a novel coronavirus (Middle East respiratory syndrome coronavirus, or MERS-CoV) that was first identified in Saudi Arabia in 2012. Typical MERS symptoms include fever, cough and shortness of breath. Some laboratory-confirmed cases of MERS-CoV infection are reported as asymptomatic, meaning that they do not have any clinical symptoms, yet they are positive for MERS following a laboratory test.

 

WHO (2017). Middle East respiratory syndrome coronavirus fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/mers-cov/en/ (27 Nov 2017).

Influenza A (H7N9) is an avian influenza virus that was first reported in 2013 in China. The 2016-2017 season was the largest seasonal "wave" since the virus was first identified. Despite the increased number of human cases, the WHO indicated in December 2017 that no significant changes in virus properties or the epidemiology of human infections has been observed.

 

WHO (2017). Influenza at the human-animal interface: Summary and assessment, 30 October to 7 December 2017. Retrieved from:

http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_12_07_2017.pdf?ua=1 (01 February 2018).

Our Platform

Insights must be actionable, global and dynamic.

We can confront infectious disease risk for a simple reason — we have best-in-class models informed by the most comprehensive epidemiological database ever created. Our platform processes hundreds of data sources covering historical pandemics to emerging outbreaks.

Learn more
Our Mission

We strive to make the world more resilient to epidemics.

We believe that working with the insurance industry and governmental organizations on improved techonologies is one of the best ways to help mitigate the impact of infectious diseases.

Insurance

Metabiota's offering enables reinsurers and insurers to accurately quantify complex infectious disease risk. Whether it's to create novel insurance products or improve capital utilization and enterprise risk management, Metabiota partners with customers to improve insurability through better understanding and analysis of underlying exposure.

Government

Government agencies responsible for outbreak response planning and implementation leverage Metabiota's platform to assess preparedness and conduct what-if analyses to ensure readiness for events of varying impact.